•
AC
ACHV
Achieve Life Sciences, Inc.
yahooIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
--
Price Chart
Market Cap
288.53M
Volume
839.09K
52W High
$6.03
52W Low
$1.84
Open
$0.00
Prev Close
$5.49
Day Range
0.00 - 0.00
About Achieve Life Sciences, Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Latest News
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Benzinga•Dec 17
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
GlobeNewswire Inc.•Jun 30
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
GlobeNewswire Inc.•Jun 27
Achieve Life Sciences Announces Proposed Underwritten Public Offering
Benzinga•Jun 26
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
GlobeNewswire Inc.•Mar 11
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline
GlobeNewswire Inc.•Oct 16
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
GlobeNewswire Inc.•May 17
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire Inc.•May 9